Yoon‐Koo Kang - Researcher Profile

Publications

2 shown

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng , Yoon‐Koo Kang , Zhendong Chen +18 more

Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safe...

2008 The Lancet Oncology 5750 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 7,343
Institution: Asan Medical Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0783-6583

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.